(0.33%) 5 116.84 points
(0.32%) 38 363 points
(0.38%) 15 989 points
(-0.99%) $83.02
(5.51%) $2.03
(0.32%) $2 354.70
(0.47%) $27.67
(4.12%) $960.05
(-0.26%) $0.932
(-0.44%) $10.98
(-0.55%) $0.796
(1.66%) $93.40
@ $2.22
発行日: 14 2月 2024 @ 23:33
リターン: -11.88%
前回のシグナル: 2月 14 - 05:01
前回のシグナル:
リターン: 1.14 %
Live Chart Being Loaded With Signals
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe...
Stats | |
---|---|
本日の出来高 | 121 418 |
平均出来高 | 532 750 |
時価総額 | 175.14M |
EPS | $0 ( 2024-03-05 ) |
次の収益日 | ( $-0.100 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.32 |
ATR14 | $0.00900 (0.46%) |
ボリューム 相関
Compugen Ltd 相関
10 最も負の相関 | |
---|---|
ULTA | -0.945 |
ASO | -0.925 |
SBNYP | -0.915 |
TTCF | -0.889 |
OPTN | -0.888 |
CDAK | -0.884 |
CPRX | -0.88 |
PHCF | -0.87 |
BNIXU | -0.87 |
FANH | -0.869 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Compugen Ltd 相関 - 通貨/商品
Compugen Ltd 財務諸表
Annual | 2023 |
収益: | $33.46M |
総利益: | $30.98M (92.59 %) |
EPS: | $-0.210 |
FY | 2023 |
収益: | $33.46M |
総利益: | $30.98M (92.59 %) |
EPS: | $-0.210 |
FY | 2022 |
収益: | $7.50M |
総利益: | $6.53M (87.00 %) |
EPS: | $-0.390 |
FY | 2021 |
収益: | $6.00M |
総利益: | $5.32M (88.67 %) |
EPS: | $-0.410 |
Financial Reports:
No articles found.
Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。